Why Tetraphase Pharmaceuticals Inc. Shares Spiked Higher

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Tetraphase Pharmaceuticals (NASDAQ: TTPH  ) , a clinical-stage biopharmaceutical company focused on developing therapies to treat multi-drug-resistant infections, spiked higher by as much as 13% after reporting its third-quarter earnings results.

So what: For the quarter, Tetraphase reported a 14.6% decline in revenue to $2.2 million from the year-ago period as its net loss more than tripled to $10.1 million from just $3.1 million in the prior year. Due to the company recently going public, however, Tetraphase's net loss dipped to $0.49 per share from $9.63 per share in the previous year. By comparison, Wall Street had been expecting a narrower loss of just $0.42 per share. The real excitement here is that the company announced its quarterly highlights which included the first phase 3 dosing of lead drug candidate eravacycline for the treatment of intra-abdominal infections, and confirmed a second phase 3 trial involving eravacycline in an IV-to-oral step-down as a treatment of complicated urinary tract infection.

Now what: This has been a theme this year in the biotech sector -- pumping up recently IPO'd biotechs after they announce the first dosing of a mid- or late-stage trial. While I'm not saying that shareholders shouldn't be excited about eravacycline's potential, I am suggesting that it might be best to wait for the top-line data before betting significantly on Tetraphase's future. You could potentially miss out on a big pop this way, but you'll set yourself up for potentially safer long-term returns.

The growth stock you should be watching instead
There's little denying that Tetraphase Pharmaceuticals has big potential -- but so does this incredible tech stock, which is growing twice as fast as Google and Facebook, and more than three times as fast as and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this company will be a huge winner in 2013 and beyond. Just click here to watch!

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2727140, ~/Articles/ArticleHandler.aspx, 9/24/2016 10:05:23 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,261.45 -131.01 -0.71%
S&P 500 2,164.69 -12.49 -0.57%
NASD 5,305.75 -33.78 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/23/2016 4:00 PM
TTPH $3.83 Down -0.04 -1.03%
Tetraphase Pharmac… CAPS Rating: ****